[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
.

Avastin and cetuximab do not enhance the effects of gemcitabine in the treatment of advanced pancreatic cancer

Two studies (both multicentre American studies) reported at The American Society of Clinical Oncology Meeting this year looked at the addition of two 'molecular' agents, bevacizumab (avastin) and cetuximab, to the standard first line chemotherapy for advanced pancreatic cancer, gemcitabine. Neither found that these interesting compounds added to the response rates of the basic chemotherapy regime. This is a set back to the attempts to enhance the response rates in  this disease, and surprising in that early studies had suggested that the addition of cetuximab, in particular, would improve the results.


Get an opinion from a leading UK cancer specialist

Our online medical opinion service provides you with expert advice on treatment options from one of our leading cancer specialists. Complete the form for a response within 24 hours.

Ask for advice

 

Find a cancer specialist

Search our online database of private cancer specialists across the UK, or select one of our featured oncologists and cancer specialists.

Find a specialist